These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 18077992)
21. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Lee AK; Levy LB; Cheung R; Kuban D Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415 [TBL] [Abstract][Full Text] [Related]
22. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow. Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849 [TBL] [Abstract][Full Text] [Related]
23. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen. Zagars GK; Pollack A; von Eschenbach AC Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892 [TBL] [Abstract][Full Text] [Related]
24. Rising prostate-specific antigen after primary treatment of prostate cancer: sequential hormone manipulation. Schmid HP; Keuler FU; Altwein JE Urol Int; 2007; 79(2):95-104. PubMed ID: 17851276 [TBL] [Abstract][Full Text] [Related]
25. Salvage options for biochemical recurrence after primary therapy for prostate cancer. Bong GW; Keane TE Can J Urol; 2007 Dec; 14 Suppl 1():2-9. PubMed ID: 18163938 [TBL] [Abstract][Full Text] [Related]
26. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy. D'Amico A BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162 [TBL] [Abstract][Full Text] [Related]
27. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ? MacDonald OK; Schild SE; Vora S; Andrews PE; Ferrigni RG; Novicki DE; Swanson SK; Wong WW Urology; 2004 Oct; 64(4):760-4. PubMed ID: 15491716 [TBL] [Abstract][Full Text] [Related]
28. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence. Malik RD; Goldberg JD; Hochman T; Lepor H Eur Urol; 2011 Sep; 60(3):548-53. PubMed ID: 21652145 [TBL] [Abstract][Full Text] [Related]
29. The value of radiotherapy in treating recurrent prostate cancer after radical prostatectomy. Stephenson AJ; Slawin KM Nat Clin Pract Urol; 2004 Dec; 1(2):90-6. PubMed ID: 16474521 [TBL] [Abstract][Full Text] [Related]
30. Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy. Van Poppel H; Joniau S; Van Cleynenbreugel B; Mottaghy FM; Oyen R Prostate Cancer Prostatic Dis; 2009; 12(2):116-23. PubMed ID: 19238169 [TBL] [Abstract][Full Text] [Related]
31. Effects of commercially available soy products on PSA in androgen-deprivation-naïve and castration-resistant prostate cancer. Joshi M; Agostino NM; Gingrich R; Drabick JJ South Med J; 2011 Nov; 104(11):736-40. PubMed ID: 22024780 [TBL] [Abstract][Full Text] [Related]
32. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. Amling CL; Lerner SE; Martin SK; Slezak JM; Blute ML; Zincke H J Urol; 1999 Mar; 161(3):857-62; discussion 862-3. PubMed ID: 10022701 [TBL] [Abstract][Full Text] [Related]
33. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA. Jang JW; Hwang WT; Guzzo TJ; Wein AJ; Haas NB; Both S; Vapiwala N Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1493-9. PubMed ID: 22401922 [TBL] [Abstract][Full Text] [Related]
34. PSA relapse prostate cancer: the importance of tailored therapy. Aranha O; Vaishampayan U Urol Oncol; 2004; 22(1):62-9. PubMed ID: 14969807 [TBL] [Abstract][Full Text] [Related]
35. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy. Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941 [TBL] [Abstract][Full Text] [Related]
36. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776 [TBL] [Abstract][Full Text] [Related]
37. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Bianco FJ; Scardino PT; Stephenson AJ; Diblasio CJ; Fearn PA; Eastham JA Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):448-53. PubMed ID: 15890586 [TBL] [Abstract][Full Text] [Related]
38. Long-term follow-up and risk of cancer death after radiation for post-prostatectomy rising prostate-specific antigen. Swanson GP; Du F; Michalek JE; Hermans M Int J Radiat Oncol Biol Phys; 2011 May; 80(1):62-8. PubMed ID: 20646861 [TBL] [Abstract][Full Text] [Related]
39. Methodology of patient care for elevated PSA after prostate cancer treatment: A primary care perspective. Baum N; Levy J Postgrad Med; 2015 Aug; 127(6):654-9. PubMed ID: 26118565 [TBL] [Abstract][Full Text] [Related]